Financing
Stock option proceeds and other, net
Bristol-Myers Squibb Stock option proceeds and other, net decreased by 197.0% to -$98.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 4.9%, from -$103.00M to -$98.00M. Over 2 years (FY 2022 to FY 2025), Stock option proceeds and other, net shows a downward trend with a -62.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementCash Flow Statement
SectionFinancing
CategoryEfficiency
SignalHigher is better
VolatilityModerate
First reportedQ1 2022
Last reportedQ1 2026Apr 30, 2026
How to read this metric
Positive values indicate cash inflows from option exercises, while negative values reflect net payments or tax-related settlements.
Detailed definition
Net cash flows resulting from the exercise of employee stock options and related equity-based compensation activities. T...
Peer comparison
Standard line item for companies with significant equity-based compensation programs.
Metric ID:
financing_payments_for_proceeds_from_stock_option_exerci_0756b8Historical Data
16 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $333.00M | $419.00M | $53.00M | $179.00M | -$92.00M | $53.00M | $41.00M | $25.00M | -$97.00M | -$6.00M | -$19.00M | -$103.00M | $0.00 | -$3.00M | -$33.00M | -$98.00M |
| QoQ Change | — | +25.8% | -87.4% | +237.7% | -151.4% | +157.6% | -22.6% | -39.0% | -488.0% | +93.8% | -216.7% | -442.1% | +100.0% | — | <-999% | -197.0% |
| YoY Change | — | — | — | — | -127.6% | -87.4% | -22.6% | -86.0% | -5.4% | -111.3% | -176.0% | -6.2% | +100.0% | — | -73.7% | +4.9% |
Range-$103.00M – $419.00M
CAGR-27.8%
Avg YoY Growth-53.8%
Median YoY Growth-73.7%
Current Streak2+ quarters decline
Stock option proceeds and other, net at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's stock option proceeds and other, net?
- Bristol-Myers Squibb (BMY) reported stock option proceeds and other, net of -$98.00M in Q1 2026.
- How has Bristol-Myers Squibb's stock option proceeds and other, net changed year-over-year?
- Bristol-Myers Squibb's stock option proceeds and other, net increased by 4.9% year-over-year, from -$103.00M to -$98.00M.
- What is the long-term trend for Bristol-Myers Squibb's stock option proceeds and other, net?
- Over 2 years (2022 to 2025), Bristol-Myers Squibb's stock option proceeds and other, net has grown at a -62.4% compound annual growth rate (CAGR), from $984.00M to -$139.00M.
- What does stock option proceeds and other, net mean?
- Net cash received from employees exercising stock options.